Johnson & Johnson’s (JNJ) Outperform Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Johnson & Johnson (NYSE:JNJ) in a report issued on Tuesday, Benzinga reports. They currently have a $175.00 price target on the stock.

JNJ has been the subject of several other reports. TD Securities dropped their price target on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Morgan Stanley boosted their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an equal weight rating in a research report on Thursday, July 18th. HSBC upgraded Johnson & Johnson from a hold rating to a buy rating and boosted their price target for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Daiwa America cut Johnson & Johnson from a strong-buy rating to a hold rating in a research report on Tuesday, July 23rd. Finally, Cantor Fitzgerald reiterated an overweight rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, July 1st. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $173.00.

Johnson & Johnson Trading Up 2.1 %

Shares of NYSE:JNJ opened at $164.14 on Tuesday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a market capitalization of $395.12 billion, a PE ratio of 10.23, a PEG ratio of 2.59 and a beta of 0.52. The business has a 50 day moving average of $149.73 and a two-hundred day moving average of $153.19. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.80 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Institutional Trading of Johnson & Johnson

Several institutional investors have recently added to or reduced their stakes in JNJ. Symphony Financial Ltd. Co. lifted its stake in Johnson & Johnson by 117.9% during the 4th quarter. Symphony Financial Ltd. Co. now owns 20,471 shares of the company’s stock worth $3,292,000 after acquiring an additional 11,076 shares in the last quarter. Compton Wealth Advisory Group LLC lifted its stake in Johnson & Johnson by 5.9% during the 4th quarter. Compton Wealth Advisory Group LLC now owns 11,686 shares of the company’s stock worth $1,832,000 after acquiring an additional 650 shares in the last quarter. Zullo Investment Group Inc. lifted its stake in Johnson & Johnson by 5.2% during the 4th quarter. Zullo Investment Group Inc. now owns 17,284 shares of the company’s stock worth $2,709,000 after acquiring an additional 847 shares in the last quarter. Sharkey Howes & Javer lifted its stake in Johnson & Johnson by 5.0% during the 4th quarter. Sharkey Howes & Javer now owns 1,879 shares of the company’s stock worth $295,000 after acquiring an additional 90 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC increased its holdings in Johnson & Johnson by 3.1% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 9,416 shares of the company’s stock worth $1,476,000 after purchasing an additional 284 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.